March 21 (Reuters) - The U.S. FDA has approved privately held Italfarmaco Group's drug to treat Duchenne muscular dystrophy (DMD), an inherited muscle-wasting disorder, the health regulator said on Thursday.
(Reporting by Sruthi Narasimha Chari and Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri)
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential.
The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.
The U.S. birth rate from 2023 was down 2% from 2022, according to the Centers for Disease Control and Prevention.
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.
SNY earnings call for the period ending March 31, 2024.
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
Long-term care in residential facilities like nursing homes is a financial challenge for many. When dealing with a loved one who is disabled, elderly or ill, families often try every other kind of long-term care facility first. Because nursing homes … Continue reading → The post Nursing Home Costs: How You Can Cover Them appeared first on SmartAsset Blog.
Mental-health problems often follow brain injuries. U.S. doctors are helping their Ukrainian counterparts, and learning from them.